Excalibur Management Corp Sells 35 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Excalibur Management Corp trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 799 shares of the medical research company’s stock after selling 35 shares during the quarter. Excalibur Management Corp’s holdings in Thermo Fisher Scientific were worth $416,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of TMO. Legacy Investment Solutions LLC bought a new stake in Thermo Fisher Scientific during the third quarter valued at about $26,000. Barrett & Company Inc. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $28,000. FPC Investment Advisory Inc. bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $28,000. Missouri Trust & Investment Co acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $29,000. Finally, Pillar Financial Advisors LLC purchased a new position in Thermo Fisher Scientific in the fourth quarter worth $29,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on TMO shares. Wells Fargo & Company boosted their target price on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. Royal Bank of Canada set a $693.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 31st. UBS Group raised their price target on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a report on Friday, January 31st. Finally, Citigroup dropped their price objective on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $653.23.

Insiders Place Their Bets

In related news, CFO Stephen Williamson sold 9,825 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the completion of the sale, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. This trade represents a 26.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. This represents a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock valued at $13,106,062 over the last ninety days. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Down 1.2 %

NYSE TMO opened at $513.77 on Wednesday. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The business has a fifty day moving average price of $544.56 and a 200 day moving average price of $554.22. The company has a market cap of $193.83 billion, a P/E ratio of 31.08, a P/E/G ratio of 2.99 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be issued a $0.43 dividend. The ex-dividend date is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.33%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio is currently 10.41%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.